UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 6,783,965 B1
APPLICATION NO. : 09/501730
DATED : August 31, 2004
INVENTOR(S) : Sherman et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

On the Title page of the patent, please replace exemplary drawing FIG. 1 with corrected FIG. 1.

Also, please replace FIG. 1 and FIG. 5 with corrected replacement figures attached herein.

Signed and Sealed this

First Day of September, 2009

David J. Kappos

David J. Kappos
Director of the United States Patent and Trademark Office

(12) **United States Patent**
Sherman et al.

(10) **Patent No.: US 6,783,965 B1**
(45) **Date of Patent: *Aug. 31, 2004**

(54) **AGGREGATE-FREE URATE OXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES**

(75) Inventors: **Merry R. Sherman**, San Carlos, CA (US); **Mark G. P. Saifer**, San Carlos, CA (US); **L. David Williams**, Fremont, CA (US)

(73) Assignee: **Mountain View Pharmaceuticals, Inc.**, Menlo Park, CA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **09/501,730**

(22) Filed: **Feb. 10, 2000**

(51) **Int. Cl.**[7] **C12N 9/04**; C12N 15/00; A61K 38/44; C07K 1/00; C07H 21/04

(52) **U.S. Cl.** **435/190**; 435/191; 435/440; 424/94.4; 536/23.2; 530/350

(58) **Field of Search** 435/190, 191, 435/440, 170; 424/94.4, 94.6; 536/23.2; 530/350, 413

(56) **References Cited**

U.S. PATENT DOCUMENTS

3,616,231	A	10/1971	Bergmeyer et al.	
4,460,683	A	7/1984	Gloger et al.	
4,766,106	A	8/1988	Katre et al.	
4,847,325	A	7/1989	Shadle et al.	
4,917,888	A	4/1990	Katre et al.	
5,286,637	A	2/1994	Veronese et al.	435/183
5,382,518	A	1/1995	Caput et al.	
5,428,128	A	6/1995	Mensi-Fathi et al.	
5,541,098	A	7/1996	Caput et al.	
5,612,460	A	3/1997	Zalipsky	
5,643,575	A	7/1997	Martinez et al.	424/194.1
5,653,974	A	8/1997	Hung et al.	
5,811,096	A *	9/1998	Aleman et al.	424/94.4
5,880,255	A	3/1999	Delgado et al.	
5,919,455	A	7/1999	Greenwald et al.	
6,576,235	B1 *	6/2003	Williams et al.	424/94.4
2002/0010319	A1 *	1/2002	Ansaldi et al.	530/387.1

FOREIGN PATENT DOCUMENTS

DE	279 486 A1	6/1990
JP	09154581	6/1997
WO	WO 94/19007	9/1994
WO	WO 00/07629	2/2000
WO	WO 00/08196	2/2000

OTHER PUBLICATIONS

Caliceti et al. Biopharmaceutical properties of uricase conjugated to neutral and amphiphilic polymer. Bioconjugate Chem. 10, 638–646. (1999).*

(List continued on next page.)

Primary Examiner—Ponnathapu Achutamurthy
Assistant Examiner—Yong Pak
(74) *Attorney, Agent, or Firm*—Sterne, Kessler, Goldstein & Fox P.L.L.C.

(57) **ABSTRACT**

A naturally occurring or recombinant protein, especially a mutein of porcine urate oxidase (uricase), that is essentially free of large aggregates can be rendered substantially non-immunogenic by conjugation with a sufficiently small number of strands of polymer such that the bioactivity of the protein is essentially retained in the conjugate. Such conjugates are unusually well suited for treatment of chronic conditions because they are less likely to induce the formation of antibodies and/or accelerated clearance than are similar conjugates prepared from protein preparations containing traces of large aggregates.

30 Claims, 6 Drawing Sheets



U.S. Patent Aug. 31, 2004 Sheet 1 of 6 6,783,965 B1

FIG. 1



FIG. 5


UV Uricase Assays of Sera from Mice Injected with 6 x 10-kDa PEG Conjugates of PKS Uricase or of Pools from Mono Q Column Fractions
(Mice Were Bled 24 Hours after Each Weekly Injection.)
Mean Values +/- s.d., mAU / min / µL
0
5
10
15
20
25
30
35
1
2
3
4
5
6
Injection Number
High-Salt Pool
Low-Salt Pool
Unfractionated PKS Uricase
Data for the Low-Salt and High-Salt Pools were shifted on the x-axis by 0.1 and 0.2 units, respectively.